Recurrent Non-small Cell Lung Cancer Completed Phase 1 Trials for Bortezomib (DB00188)

Also known as: Non-Small Cell Lung Cancer Recurrent / Lung cancer non-small cell recurrent

IndicationStatusPhase
DBCOND0028805 (Recurrent Non-small Cell Lung Cancer)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00052338Bortezomib Plus Gemcitabine and Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung CancerTreatment